ÃâÒßѧÊÔÌâ
^B"_b?b Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
xUYN\Pc-
1. Fas(CD95)/FasL
2sd=G'7! 2. common chain of cytokine receptor
yQA"T
? 3 . TCR/CD3 complex
>*Qk~kv<% 4. negaive selection of thymocytes
qU
x7S(a 5. artificial active immune
E/ed0'|m 6. anti-idiotypic
'$L= sH5 7. IgSF
hwol7B> 8. Integrin
t"74HZO> 9. chemokine
dU04/]modD 10. B7/CD28
DrCfC[A~] ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©
#<V'gE 1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£
;uo|4?E:\( 2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£
V{aIhH>P 3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£
>, Swk3 5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½
s].Cx4VQ
~[X:twidkL 1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£
(S93 %ii µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ
V9 t:JY Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
H-y-7PW*~ 1. B7/CD28
YwTtI ID% 2. Th1 subset
'A@Oia1;{ 3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£©
O!cO/]< 4. antibody affinity maturation
WRyv
>Y 5. AP-1
Wv'B[;[) 6. single chain variable fragment£¨ScFv£©
|P?B AWYeQ 7. NK cell receptor
-8J@r2 \ 8. Zinkernagel-Doherty phenomenon
M]:B: ; 9. Ig fold
j:<T<8.o 10. CD40/CD40L
]tV{#iIJ* ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£©
CMf~Yv 1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£
/u1zRw 2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿
CZno2$8@e 3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿
8pKPbi;(2 Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩
y,eoTmaI 1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£
~9 nrS9) 2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£
!f[N&se 3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£
UE](`|4H Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
b<MMli £¨ÃâÒßѧרҵºÍרҵ»ù´¡£©
JugQ +0 Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©
_E-GHj>k
z 1.Co-stimulators (or co-stimulating molecules)
C
/VXyl@o 2.NK-kB
TV2:5@33 3.Immunoglobulin superfamily
g)Uh
4.antigen-presenting cell (APC)
sMo%Ayes 5.death domain
K1yM'6Zw 6.CCR and CXCR
-Euy5Y 7.Lectin (or mitogen)
S!c@6&XJm? 8.Clusters of differentiation, CD)
x@x@0k`
A2 9.B7 family
=swcmab; 10.Cytotoxic T lymphocyte, CTL)
#@`^
. 11.IL-15 and IL-15 receptor (IL-15R)
kF7Al]IgT 12.MHC restriction
>.A:6 13.Affinity-chromatography
r#}%s
of 14.Cyctosprin A, CsA
m]vr|:{6/ 15.Antibody-dependent cell-mediated cytotoxicity, ADCC)
EZFWxR/ ¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©
W6>uLMUa 1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿
[J#(k`@ 2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£
XsC bA8Qv 3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£
mLqm83 Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©
&kE|~i:=,9 ÃâÒßѧרҵ£º
bL%)k61G_v 1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£
XDQ1gg` Ïû»¯ÄÚ¿Æ£º
$P~ a 2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£
pQi - ѪҺ²¡Ñ§×¨Òµ£º
l@
K<p 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿
b/`'?|
C Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
Q[^d{e*l (רҵ»ù´¡: ÃâÒßѧ)
d+;~x* Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)
,\b5M`<c 1. ADCC(antibody dependent cell-mediated cytotoxicity)
:gn!3P}p? 2. »·æß¾úËØ(cyclosporin)
ty
?y&~axk 3. KIR(killer cell inhibitory receptor)
#Bjnz$KB 4. HLDA(human leucocyte differentiation antigen)
t s&C0 5. Interleukin 18(IL-18)
lDzVc`c 6. ÕûºÏËØ(integrin)
W=/B[@3' 7. Fas/FasL
$o z
ZFvJF 8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)
|ONOF 9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)
F/h)azcn 10. Th1/Th2
8in8_/x 11. »ùÒòÒßÃç(DNAÒßÃç)
` $}[np| 12. chemokines and chemokine receptor
c8'?Dd 13. ÃâÒßÄÍÊÜ
3't?%$'5 14. ¹²´Ì¼¤·Ö×Ó
h4U .wk 15. ËÀÍö½á¹¹Óò(death domain)
z
'j%.Dd8 ¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)
SRMy#j- 1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?
YS9| J=!~ 2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óá£
`ainJs:B £¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î
OF)X(bi4j £¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
8I*fPf £¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå
v+Hu=RZE £¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹
=^6]N~*,D 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£
~Oolm_+{} Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ)
3+IS7ATn ÎÊ´ðÌâ(ÿÌâ25·Ö)
~yci2{ 1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£
FG?B:Zl%T 2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿
FJ/kumq 3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£
-
iU7' 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£